In a groundbreaking study published in the Proceedings of the National Academy of Sciences on March 2, 2026, researchers from VIB and KU Leuven have upended a long-held belief about the role of microglia—the resident immune cells of the brain—in Alzheimer’s disease. Traditionally regarded as the brain’s defensive force against the buildup of amyloid plaques, these cells have now been shown to actively facilitate the formation of these toxic aggregates, heralding a paradigm shift in our understanding of neurodegenerative pathology.
For decades, microglia were primarily seen through the lens of neuroprotection, tasked with the clearance of amyloid-beta (Aβ) peptides which accumulate abnormally in Alzheimer’s patients. These peptides clump together to form plaques, one of the hallmark pathological features of the disease. However, the novel research led by Professor Joost Schymkowitz and Professor Frederic Rousseau reveals that microglia do more than merely respond to plaques—they actually generate fibrillar amyloid structures themselves during early disease stages.
The study unearths a previously unrecognized duality in microglial function. Far from passively engulfing plaques, microglia actively remodel soluble amyloid-beta 42 (Aβ42) peptides into extracellular fibrils with a high seeding capacity. Seeding refers to the process by which existing fibrils induce further aggregation of soluble peptides, accelerating plaque formation. This slicing-edge discovery highlights microglia not just as scavengers but also as catalysts in plaque nucleation, suggesting that many amyloid deposits in the Alzheimer’s brain might arise as a result of cellular activity rather than spontaneous aggregation alone.
This redefinition of microglial activity challenges existing therapeutic strategies that focus on stimulating these immune cells to enhance plaque clearance. The study suggests that such therapies might be a double-edged sword, with microglia possibly exacerbating plaque buildup under certain conditions, especially in the earlier phases of the disease. These findings advocate for a more nuanced approach, one that considers the timing and context of microglial activation to prevent unwittingly promoting neurodegeneration.
Structurally, amyloid plaques found in patients differ significantly from those formed under laboratory conditions. This discrepancy has long confounded researchers striving to develop effective experimental models. The VIB-KU Leuven team addresses this by demonstrating that microglia-generated amyloid fibrils more closely mimic the structures isolated from Alzheimer’s brain tissue, offering a refined and more physiologically relevant model for studying plaque formation and its downstream effects on neural health.
According to Professor Schymkowitz, traditional in vitro aggregation assays have failed to capture the complexity of amyloid fibrillogenesis as it occurs in vivo. The microglia-based model introduced in this study provides a fresh lens through which to analyze the atomic architecture of amyloid fibrils. Understanding the precise structural mimicry between patient-derived and microglia-generated fibrils paves the way for designing drugs that specifically target the pathogenic forms of amyloid-beta, potentially enhancing therapeutic efficacy and precision.
The cellular mechanisms underlying microglial facilitation of fibrillogenesis are thought to involve remodeling of Aβ42 peptides into fibrillar conformations post-phagocytosis. This finding reframes microglia from passive bystanders to active participants in disease progression, with their phagocytic machinery inadvertently aiding the creation of new amyloid seeds that propagate the spread of plaques throughout the brain’s intricate neural networks.
Microglia’s involvement extends beyond plaque formation; their seeding-competent amyloid fibrils possess cross-seeding activity. This means that fibrils generated by microglia can promote the aggregation of other amyloidogenic proteins, potentially linking amyloid pathology with other protein misfolding diseases. Such cross-talk may exacerbate neurodegeneration, indicating that microglial modulation could have wide-reaching implications beyond Alzheimer’s alone.
The implications of these findings are vast and multifaceted. With nearly 55 million people worldwide living with Alzheimer’s, and no cure to date, the study offers a crucial window into the very earliest molecular events that dictate disease onset and progression. It underscores the necessity for therapeutic strategies to be tailored not only to the type of immune response but also to the timing within the disease timeline.
Professor Rousseau highlights that the better physiological relevance of this microglia-based model allows researchers to probe not only the biophysical properties of amyloid fibrils but also the cellular responses they elicit. Studying these interactions in a model that faithfully represents patient-derived amyloid structures will accelerate the discovery of biomarkers and drug candidates specifically aimed at halting or reversing early neurodegenerative changes.
Moreover, this discovery offers a plausible explanation for why some clinical trials aimed at boosting microglial clearance mechanisms have failed or produced disappointing results. Without accounting for microglia’s capacity to generate amyloid seeds, such interventions could inadvertently shift microglial activity toward a harmful amyloidogenic phenotype, aggravating rather than ameliorating disease symptoms.
In conclusion, this seminal research reframes microglia from mere defenders to complex modulators in the Alzheimer’s disease landscape. By actively generating seeding-competent amyloid fibrils and driving plaque formation, these immune cells reveal an unexpected vulnerability in the brain’s defense system. This knowledge compels the scientific community to rethink how immunomodulatory therapies are designed, emphasizing the importance of targeting microglia function with precision, safeguarding their beneficial roles while curbing their contribution to pathology.
Subject of Research: Cells
Article Title: Phagocytes as Plaque Catalysts: Human Macrophages Generate Seeding-Competent Aβ42 Fibrils with Cross-Seeding Activity
News Publication Date: 10 March 2026
References: Proceedings of the National Academy of Sciences, 2 March 2026 publication
Keywords: Neuroscience, Molecular biology, Cell biology, Alzheimer’s disease, Microglia, Amyloid-beta, Amyloid plaques, Neurodegeneration, Protein aggregation, Phagocytosis, Seeding activity
Tags: Alzheimer’s disease microglia roleamyloid-beta 42 peptide aggregationamyloid-beta plaque formationbrain immune cells in neurodegenerationearly-stage Alzheimer’s disease mechanismsmicroglia amyloid fibril generationmicroglia dual role in amyloid clearance and formationmicroglial contribution to Alzheimer’s pathologyneuroimmune interactions in brain disordersneuroinflammation in Alzheimer’sseeding mechanism in amyloid plaquesVIB KU Leuven Alzheimer’s research
